title: Serum protein profile of rheumatoid arthritis treated with anti-TNF therapy (infliximab).
abstract: We analyzed the changes in the serum protein profile by infliximab using two-dimensional gel electrophoresis and mass spectrometry. More than 50 gel spots were seen to increase or decrease in correlation with clinical improvements of RA. The spots corresponding to CRP, C3, and Apo J showed reduced staining intensity, while the spots corresponding to Apo A-I, RBP, and transthyretin were enhanced. The protein profile of RA patients treated with infliximab was mostly similar to that of normal healthy controls except for several protein spots. This suggested that infliximab normalized the serum protein profile of RA patients, leading to modification in the serum lipid profile and antioxidant status in RA.
authors.affiliation: First Department of Internal Medicine, Osaka Medical College, Daigaku-Machi 2-7, Takatsuki, Osaka 569-8686, Japan. t-takeuchi@poh.osaka-med.ac.jp
authors.forename: Tohru
authors.initials: T
authors.lastname: Takeuchi
authors.forename: Toyofumi
authors.initials: T
authors.lastname: Nakanishi
authors.forename: Yoko
authors.initials: Y
authors.lastname: Tabushi
authors.forename: Ayu
authors.initials: A
authors.lastname: Hata
authors.forename: Takeshi
authors.initials: T
authors.lastname: Shoda
authors.forename: Takuya
authors.initials: T
authors.lastname: Kotani
authors.forename: Akira
authors.initials: A
authors.lastname: Shimizu
authors.forename: Takayuki
authors.initials: T
authors.lastname: Takubo
authors.forename: Shigeki
authors.initials: S
authors.lastname: Makino
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Hanafusa
mesh_terms: D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy*; D001798:Blood Proteins / Q000032:analysis*; D002648:Child; D002675:Child, Preschool; D002846:Chromatography, Affinity; D005260:Female; D006801:Humans; D007223:Infant; D000069285:Infliximab; D008297:Male
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D001798:Blood Proteins; D000069285:Infliximab